LifeStance Health (LFST) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 02, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Entity Registrant Name	LifeStance Health Group, Inc.
Entity Central Index Key	0001845257
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	LFST
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		378,005,241
Entity File Number	001-40478
Entity Tax Identification Number	86-1832801
Entity Address, Address Line Two	Suite 6000
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4800 N. Scottsdale Road
Entity Address, City or Town	Scottsdale
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85251
City Area Code	602
Local Phone Number	767-2100

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 79,605	$ 108,621
Patient accounts receivable, net	121,796	100,868
Prepaid expenses and other current assets	36,480	23,734
Total current assets	237,881	233,223
NONCURRENT ASSETS
Property and equipment, net	193,144	194,189
Right-of-use assets	191,381	199,431
Intangible assets, net	243,788	263,294
Goodwill	1,293,502	1,272,939
Other noncurrent assets	11,221	10,795
Total noncurrent assets	1,933,036	1,940,648
Total assets	2,170,917	2,173,871
CURRENT LIABILITIES
Accounts payable	8,044	12,285
Accrued payroll expenses	81,144	75,650
Other accrued expenses	34,348	30,428
Current portion of contingent consideration	10,537	15,876
Operating lease liabilities, current	43,446	38,824
Other current liabilities	3,335	2,936
Total current liabilities	180,854	175,999
NONCURRENT LIABILITIES
Long-term debt, net	248,718	225,079
Operating lease liabilities, noncurrent	205,586	212,586
Deferred tax liability, net	38,324	38,701
Other noncurrent liabilities	2,559	2,783
Total noncurrent liabilities	495,187	479,149
Total liabilities	676,041	655,148
COMMITMENTS AND CONTINGENCIES (see Note 12)
STOCKHOLDERS' EQUITY
Preferred stock - par value $0.01 per share; 25,000 shares authorized as of June 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of June 30, 2023 and December 31, 2022	0	0
Common stock - par value $0.01 per share; 800,000 shares authorized as of June 30, 2023 and December 31, 2022; 378,005 and 375,964 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	3,782	3,761
Additional paid-in capital	2,141,247	2,084,324
Accumulated other comprehensive income	4,151	3,274
Accumulated deficit	(654,304)	(572,636)
Total stockholders' equity	1,494,876	1,518,723
Total liabilities and stockholders' equity	$ 2,170,917	$ 2,173,871

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	800,000,000	800,000,000
Common Stock, Shares, Issued	378,005,000	375,964,000
Common Stock, Shares, Outstanding	378,005,000	375,964,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
TOTAL REVENUE	$ 259,578	$ 209,527	$ 512,167	$ 412,622
OPERATING EXPENSES
Center costs, excluding depreciation and amortization shown separately below	186,607	149,697	369,594	298,590
General and administrative expenses	101,854	103,559	186,480	206,928
Depreciation and amortization	19,530	16,743	38,599	32,427
Total operating expenses	307,991	269,999	594,673	537,945
LOSS FROM OPERATIONS	(48,413)	(60,472)	(82,506)	(125,323)
OTHER INCOME (EXPENSE)
Gain (loss) on remeasurement of contingent consideration	1,539	(180)	2,576	(614)
Transaction costs	(3)	(19)	(89)	(297)
Interest expense, net	(5,119)	(7,133)	(10,211)	(10,574)
Other expense	(24)	0	(69)	0
Total other expense	(3,607)	(7,332)	(7,793)	(11,485)
LOSS BEFORE INCOME TAXES	(52,020)	(67,804)	(90,299)	(136,808)
INCOME TAX BENEFIT (PROVISION)	6,542	(923)	10,579	5,753
NET LOSS	$ (45,478)	$ (68,727)	$ (79,720)	$ (131,055)
NET LOSS PER SHARE, BASIC	$ (0.13)	$ (0.19)	$ (0.22)	$ (0.37)
NET LOSS PER SHARE, DILUTED	$ (0.13)	$ (0.19)	$ (0.22)	$ (0.37)
Weighted-average shares, basic net loss per share	363,161	353,729	362,039	352,297
Weighted-average shares, diluted net loss per share	363,161	353,729	362,039	352,297
Net Income (Loss)	$ (45,478)	$ (68,727)	$ (79,720)	$ (131,055)
OTHER COMPREHENSIVE INCOME
Unrealized gains on cash flow hedge, net of tax	2,147	0	877	0
COMPREHENSIVE LOSS	$ (43,331)	$ (68,727)	$ (78,843)	$ (131,055)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2021	$ 1,545,028	$ 3,743	$ 1,898,357		$ (357,072)
Shares, Outstanding at Dec. 31, 2021		374,255
Net Income (Loss)	(131,055)				(131,055)
Issuance of common stock upon vesting of restricted stock units	(37)	$ 20	(57)
Issuance of common stock upon vesting of restricted stock units, Shares		1,954
Forfeitures, value	(185)		(185)
Forfeitures, shares		(28)
Stock-based compensation expense	117,550		117,550
Balance at Jun. 30, 2022	1,531,301	$ 3,763	2,015,665		(488,127)
Shares, Outstanding at Jun. 30, 2022		376,181
Balance at Mar. 31, 2022	1,542,518	$ 3,744	1,958,174		(419,400)
Shares, Outstanding at Mar. 31, 2022		374,323
Net Income (Loss)	(68,727)				(68,727)
Issuance of common stock upon vesting of restricted stock units		$ 19	(19)
Issuance of common stock upon vesting of restricted stock units, Shares		1,858
Stock-based compensation expense	57,510		57,510
Balance at Jun. 30, 2022	1,531,301	$ 3,763	2,015,665		(488,127)
Shares, Outstanding at Jun. 30, 2022		376,181
Balance at Dec. 31, 2022	1,518,723	$ 3,761	2,084,324	$ 3,274	(572,636)
Shares, Outstanding at Dec. 31, 2022		375,964
Net Income (Loss)	(79,720)				(79,720)
Issuance of common stock upon vesting of restricted stock units		$ 40	(40)
Issuance of common stock upon vesting of restricted stock units, Shares		4,006
Forfeitures, value	(3,399)	$ (19)	(3,380)
Forfeitures, shares		(1,965)
Other comprehensive income	877			877
Adoption of ASU 2016-13	(1,948)				(1,948)
Stock-based compensation expense	60,343		60,343
Balance at Jun. 30, 2023	1,494,876	$ 3,782	2,141,247	4,151	(654,304)
Shares, Outstanding at Jun. 30, 2023		378,005
Balance at Mar. 31, 2023	1,505,129	$ 3,767	2,108,184	2,004	(608,826)
Shares, Outstanding at Mar. 31, 2023		376,537
Net Income (Loss)	(45,478)				(45,478)
Issuance of common stock upon vesting of restricted stock units		$ 23	(23)
Issuance of common stock upon vesting of restricted stock units, Shares		2,295
Forfeitures, value	(34)	$ (8)	(26)	0	0
Forfeitures, shares		(827)
Other comprehensive income	2,147			2,147	0
Stock-based compensation expense	33,112		33,112	0	0
Balance at Jun. 30, 2023	$ 1,494,876	$ 3,782	$ 2,141,247	$ 4,151	$ (654,304)
Shares, Outstanding at Jun. 30, 2023		378,005

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (79,720)	$ (131,055)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	38,599	32,427
Non-cash operating lease costs	20,263	0
Stock-based compensation	56,944	117,365
Loss on debt extinguishment	0	3,380
Amortization of discount and debt issue costs	1,076	748
(Gain) loss on remeasurement of contingent consideration	(2,576)	614
Other, net	2,708	0
Change in operating assets and liabilities, net of businesses acquired:
Patient accounts receivable, net	(20,558)	(21,900)
Prepaid expenses and other current assets	(15,176)	(5,351)
Accounts payable	(5,395)	1,731
Accrued payroll expenses	5,158	(289)
Operating lease liabilities	(16,929)	0
Other accrued expenses	7,282	13,471
Net cash (used in) provided by operating activities	(8,324)	11,141
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(19,310)	(53,775)
Acquisitions of businesses, net of cash acquired	(19,820)	(35,118)
Net cash used in investing activities	(39,130)	(88,893)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from long-term debt, net of discount	25,000	228,000
Payments of debt issue costs	(188)	(7,184)
Payments of long-term debt	(1,173)	(181,230)
Prepayment for debt paydown	0	(1,609)
Payments of contingent consideration	(5,201)	(11,090)
Taxes related to net share settlement of equity awards	0	(478)
Net cash provided by financing activities	18,438	26,409
NET DECREASE IN CASH AND CASH EQUIVALENTS	(29,016)	(51,343)
Cash and Cash Equivalents - Beginning of period	108,621	148,029
CASH AND CASH EQUIVALENTS – END OF PERIOD	79,605	96,686
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest, net	9,830	4,927
Cash paid for taxes, net of refunds	313	860
SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND FINANCING ACTIVITIES
Equipment financed through finance leases	0	256
Contingent consideration incurred in acquisitions of businesses	1,985	5,683
Acquisition of property and equipment included in liabilities	$ 6,238	$ 13,055

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (45,478)	$ (68,727)	$ (79,720)	$ (131,055)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of the Business

Nature of the Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	NOTE 1 NATURE OF THE BUSINESS Description of Business LifeStance Health Group, Inc. ("LifeStance" or the "Company") operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company's significant accounting policies are discussed in Note 2 "Summary of Significant Accounting Policies" in Item 15 of its Annual Report on Form 10-K for the year ended December 31, 2022. During the six months ended June 30, 2023, there have been no significant changes to these policies other than the addition to the cash and cash equivalents policy further described below. Basis of Presentation and Principles of Consolidation The Company has prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the SEC regarding interim financial reporting, which include the accounts of LifeStance, its wholly-owned subsidiaries and variable interest entities ("VIEs") in which LifeStance has an interest and is the primary beneficiary. Pursuant to these rules and regulations, the Company has omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its consolidated financial condition, results of operations and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s audited financial statements for the year ended December 31, 2022 in the Company's Annual Report on Form 10-K. Use of Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a VIE. These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available information. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. The Company performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. The Company acquires and operates certain care centers which are deemed to be Friendly-Physician Entities (“FPEs”). As part of an FPE acquisition, the Company acquires 100 % of the non-medical assets, however due to legal requirements the physician-owners must retain 100% of the equity interest. The Company’s agreements with FPEs generally consist of both a Management Service Agreement, which provides for various administrative and management services to be provided by the Company to the FPE, and Stock Transfer Restriction (“STR”) agreements with the physician-owners of the FPEs, which provide for the transition of ownership interests of the FPEs under certain conditions. The outstanding voting equity instruments of the FPEs are owned by the nominee shareholders appointed by the Company under the terms of the STR agreements. The Company has the right to receive income as an ongoing management fee, which effectively absorbs all of the residual interests and has also provided financial support through loans to the FPEs. The Company has exclusive responsibility for the provision of all nonmedical services including facilities, technology and intellectual property required for the day-to-day operation and management of each of the FPEs, and makes recommendations to the FPEs in establishing the guidelines for the employment and compensation of the physicians and other employees of the FPEs. In addition, the STR agreements provide that the Company has the right to designate an appropriately licensed person(s) to purchase the equity interest of the FPE for a nominal amount in the event of a succession event at the Company’s discretion. Based on the provisions of these agreements, the Company determined that the FPEs are VIEs due to the equity holder having insufficient capital at risk, and the Company has a variable interest in the FPEs. The contractual arrangements described above allow the Company to direct the activities that most significantly affect the economic performance of the FPEs. Accordingly, the Company is the primary beneficiary of the FPEs and consolidates the FPEs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support the Company provides to the FPEs (e.g., loans) and the provisions of the contractual arrangements and nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the FPEs. Therefore, all income and expenses recognized by the FPEs are allocated to the Company. The Company does not hold interests in any VIEs for which the Company is not deemed to be the primary beneficiary. As noted previously, the Company acquires 100% of the non-medical assets of the VIEs. The aggregate carrying values of the VIEs total assets and total liabilities not purchased by the Company but included on the consolidated balance sheets were not material at June 30, 2023 and December 31, 2022 . Cash and Cash Equivalents Cash and cash equivalents include cash and highly liquid investments with original maturities of three months or less at the time of purchase. Cash and cash equivalents consist of demand deposits held with financial institutions and investments in money market funds. Emerging Growth Company Status The Company is currently an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company's unaudited consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. As of June 30, 2023, the market value of the Company's common stock held by non-affiliates exceeded $ 700 million. As a result, the Company will become a large accelerated filer beginning January 1, 2024 for future filings and will no longer be an emerging growth company. As a large accelerated filer, the Company will be subject to certain disclosure and compliance requirements that apply to other public companies but did not previously apply to the Company due to its status as an emerging growth company. These requirements include, but are not limited to: the requirement that the Company's independent registered public accounting firm attest to the effectiveness of the Company's internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002; compliance with any requirements that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditors' report providing additional information about the audit and the financial statements; the requirement that the Company provide more detailed disclosures regarding executive compensation; and, the requirement that the Company hold a non-binding advisory vote on executive compensation and obtain shareholder approval of any golden parachute payments not previously approved. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments (Topic 326)-Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires an entity to utilize a new impairment model known as the current expected credit loss (“CECL”) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The estimate of expected credit losses requires entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the standard on January 1, 2023 using the modified retrospective adoption method and did not have a material impact to the consolidated financial statements. The Company makes estimates of expected credit losses based on a combination of factors, including historical losses adjusted for current market conditions, the Company's customers' financial condition, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Total Revenue

Total Revenue	6 Months Ended
	Jun. 30, 2023
Revenues [Abstract]
Total Revenue	NOTE 3 TOTAL REVENUE The Company’s total revenue is dependent on a series of contracts with third-party payors, which is typical for providers in the health care industry. The Company has determined that the nature, amount, timing and uncertainty of revenue and cash flows are affected by the payor mix with third-party payors, which have different reimbursement rates. The payor mix of fee-for-service revenue from patients and third-party payors consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Amount % of Total Revenue Amount % of Total Revenue Amount % of Total Revenue Amount % of Total Revenue Commercial $ 235,896 91 % $ 189,061 91 % $ 464,815 91 % $ 372,670 91 % Government 10,999 4 % 9,063 4 % 21,950 4 % 17,896 4 % Self-pay 10,384 4 % 8,723 4 % 20,131 4 % 17,098 4 % Total patient service 257,279 99 % 206,847 99 % 506,896 99 % 407,664 99 % Nonpatient service 2,299 1 % 2,680 1 % 5,271 1 % 4,958 1 % Total $ 259,578 100 % $ 209,527 100 % $ 512,167 100 % $ 412,622 100 % Among the commercial payors, the table below represents insurance companies that individually represented 10 % or more of revenue: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Payor A 19 % 19 % 19 % 19 % Payor B 13 % 14 % 13 % 14 %

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	NOTE 4 PROPERTY AND EQUIPMENT, NET Property and equipment, net consists of the following: June 30, 2023 December 31, 2022 Leasehold improvements $ 162,494 $ 148,249 Computers and peripherals 27,701 26,650 Internal-use software 8,352 7,894 Furniture, fixtures and equipment 40,709 36,437 Medical equipment 950 950 Construction in process 11,285 16,892 Total $ 251,491 $ 237,072 Less: Accumulated depreciation ( 58,347 ) ( 42,883 ) Total property and equipment, net $ 193,144 $ 194,189 Depreciation expense consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Depreciation expense $ 9,354 $ 6,750 $ 18,250 $ 12,477

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	NOTE 5 LEASES The Company adopted ASC 842 on January 1, 2022 utilizing the private company effective date which did not require adoption of the new standard for any interim periods of the fiscal year in which it was adopted. As of December 31, 2022 and June 30, 2023 and for the three and six months ended June 30, 2023, the Company accounts for its leases in accordance with ASC 842. For the comparative interim periods prior to 2023, the Company prepared its quarterly unaudited consolidated financial statements in accordance with ASC 840, which is a basis different from that of the current year. Accordingly, for the comparative three and six months ended June 30, 2022 leases are presented in accordance with ASC 840. The Company leases its office facilities and office equipment which are accounted for as operating leases. Some leases contain clauses for renewal at the Company's option with renewal terms that generally extend the lease term fro m one to seven years . The components of lease expense for the Company's operating leases in its unaudited consolidated statements of operations and comprehensive loss were as follows: Three Months Ended Six Months Ended Operating lease costs $ 14,264 $ 28,572 Variable lease costs and short-term lease costs were no t material. The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows: June 30, 2023 December 31, 2022 Weighted-average remaining lease term (in years) 5.0 5.3 Weighted-average discount rate 6.77 % 6.47 % Supplemental cash flow information related to operating leases was as follows: Six Months Ended Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 30,995 Noncash lease activity Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 14,554 The future minimum lease payments under noncancellable operating leases as of June 30, 2023 are as follows: Year Ended December 31, Amount Remainder of 2023 $ 25,987 2024 64,960 2025 61,345 2026 53,713 2027 40,457 Thereafter 49,810 Total lease payments $ 296,272 Less: imputed interest ( 47,240 ) Total lease liabilities $ 249,032 The Company incurred $ 205 and $ 417 in related-party lease expense in its unaudited consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2023, respectively . The Company recognized the following amounts in its unaudited consolidated balance sheets in connection with leases with related parties: June 30, 2023 December 31, 2022 Right-of-use assets $ 2,770 $ 5,058 Operating lease liabilities, current 549 1,324 Operating lease liabilities, noncurrent 2,315 3,902 Total rent expense amounted to as follows in the unaudited consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022: Three Months Ended Six Months Ended Related-party rent expense $ 391 $ 778 Third-party rent expense 12,137 23,296 Total lease cost $ 12,528 $ 24,074

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 6 GOODWILL AND INTANGIBLE ASSETS Goodwill The following table summarizes changes in the carrying amount of goodwill: Amount Balance as of December 31, 2022 $ 1,272,939 Business acquisitions (Note 7) 20,733 Measurement period adjustments ( 170 ) Balance as of June 30, 2023 $ 1,293,502 Intangible Assets Intangible assets consist of the following: June 30, 2023 Gross Accumulated Net Weighted Regional trade names $ 36,694 $ ( 20,358 ) $ 16,336 5.0 LifeStance trade names 235,500 ( 32,791 ) 202,709 22.5 Non-competition agreements 94,535 ( 69,792 ) 24,743 4.2 Total intangible assets $ 366,729 $ ( 122,941 ) $ 243,788 December 31, 2022 Gross Accumulated Net Weighted Regional trade names $ 36,259 $ ( 16,688 ) $ 19,571 5.0 LifeStance trade names 235,500 ( 27,557 ) 207,943 22.5 Non-competition agreements 94,127 ( 58,347 ) 35,780 4.2 Total intangible assets $ 365,886 $ ( 102,592 ) $ 263,294 Gross carrying amount is based on the fair value of the intangible assets determined at the acquisition date. Total intangible asset amortization expense consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Amortization expense $ 10,176 $ 9,993 $ 20,349 $ 19,950

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2023
Business Combinations [Abstract]
Business Combinations	NOTE 7 BUSINESS COMBINATIONS During the three months ended June 30, 2022 and six months ended June 30, 2023 and 2022, the Company completed the acquisitions of 4 , 3 and 6 outpatient mental health practices, respectively. There were no completed acquisitions during the three months ended June 30, 2023. The Company accounted for the acquisitions as business combinations using the acquisition method of accounting. The purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the respective acquisition dates. Total consideration transferred for these acquisitions consisted of the following: Three Months Ended Six Months Ended June 30, June 30, 2022 2023 2022 Cash consideration $ 12,600 $ 20,000 $ 35,925 Contingent consideration, at initial fair value 3,213 1,985 5,683 Total consideration transferred $ 15,813 $ 21,985 $ 41,608 The results of the acquired businesses have been included in the Company’s consolidated financial statements beginning as of their acquisition dates. It is impracticable to provide historical supplemental pro forma financial information along with revenue and earnings subsequent to the acquisition dates for acquisitions during the period due to a variety of factors, including access to historical information and the operations of acquirees being integrated within the Company shortly after closing and not operating as discrete entities within the Company’s organizational structure. Fair Values of Assets Acquired and Liabilities Assumed The following table summarizes the preliminary fair values of assets acquired and liabilities assumed as of the dates of acquisition: Three Months Ended Six Months Ended June 30, Allocation of Purchase Price June 30, 2022 2023 2022 Cash $ 430 $ 181 $ 851 Patient accounts receivable 707 372 1,193 Prepaid expenses and other current assets 166 138 230 Property and equipment 19 221 53 Right-of-use assets — 368 — Other noncurrent assets 53 22 56 Intangible assets 901 843 1,683 Goodwill 14,526 20,733 39,227 Total assets acquired 16,802 22,878 43,293 Total liabilities assumed 989 893 1,685 Fair value of net assets $ 15,813 $ 21,985 $ 41,608 The majority of the tangible assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. The Company developed estimates for the expected future cash flows and discount rates used in the present value calculations. The following table summarizes the fair values of acquired intangible assets as of the dates of acquisition: Three Months Ended Six Months Ended June 30, June 30, 2022 2023 2022 Regional trade names (1) $ 555 $ 435 $ 897 Non-competition agreements (2) 346 408 786 Total $ 901 $ 843 $ 1,683 (1) Useful lives for regional trade names are 5 years . (2) Useful lives for non-competition agreements are 5 years . Contingent Consideration Under the provisions of the acquisition agreements, the Company may pay additional cash consideration in the form of earnouts, contingent upon the acquirees achieving certain performance and operational targets (see Note 8). The following table summarizes the maximum contingent consideration based on the acquisition agreements: Three Months Ended Six Months Ended June 30, Contingent consideration June 30, 2022 2023 2022 Maximum contingent consideration based on acquisition $ 4,200 $ 2,650 $ 7,200 Goodwill Goodwill is primarily attributable to the assembled workforce, customer and payor relationships and anticipated synergies and economies of scale expected from the integration of the businesses. The synergies include certain cost savings, operating efficiencies, and other strategic benefits projected to be achieved as a result of the acquisition. All goodwill is deductible for tax purposes.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 8 FAIR VALUE MEASUREMENTS Contingent Consideration The Company measures its contingent consideration liability at fair value on a recurring basis using Level 3 inputs. The Company estimates the fair value of the contingent consideration liability based on the likelihood and timing of the contingent earn-out payments. The following is the summary of the significant assumptions used for the fair value measurement of the contingent consideration liability as of June 30, 2023 and December 31, 2022. Valuation Technique Range of Significant Assumptions June 30, 2023 December 31, 2022 Probability-weighted analysis Probability 50 % - 100 % 50 % - 100 % based earn-outs Discount rate 9.0 % 8.0 % As of June 30, 2023 and December 31, 2022, the Company adjusted the fair value of the contingent consideration liability due to remeasurement at the reporting date. The noncurrent portion of the contingent consideration liability is included within other noncurrent liabilities on the unaudited consolidated balance sheets. Hedging Activities The Company uses derivative financial instruments, including an interest rate swap, for hedging and non-trading purposes to manage its exposure to changes in interest rates. The Company entered into a hedge transaction (interest rate swap) using a derivative financial instrument for the purpose of hedging the Company’s exposure to interest rate risks, which the contractual terms of the hedged instrument closely mirror those of the hedged item, providing a high degree of risk reduction and correlation. The objective of entering into the interest rate swap is to eliminate the variability of cash flows in the Secured Overnight Financing Rate ("SOFR") interest payments associated with the variable-rate loan over the life of the loan. In August 2022, the Company entered into an interest rate swap agreement to pay a fixed rate of 3.24 % on a total notional value of $ 189,000 of debt. As a result of the interest rate swap, 94.5 % of the term loan previously exposed to interest rate risk from changes in SOFR is now hedged against the interest rate swap at a fixed rate. The interest rate swap matures on September 30, 2025. As of June 30, 2023, the notional value was $ 187,583 . As changes in interest rates impact the future cash flow of interest payments, the hedge provides a synthetic offset to interest rate movements. The Company used the income approach to value the derivative for the interest rate swap using observable market data for all significant inputs and standard valuation techniques to convert future amounts to a single present value amount, assuming that participants are motivated but not compelled to transact. This derivative instrument (interest rate swap) is designated and qualifies as a cash flow hedge, with the entire gain or loss on the derivative reported as a component of other comprehensive income. Amounts recorded in accumulated other comprehensive income are released to earnings in the same period that the hedged transaction impacts consolidated earnings within interest expense, net. The cash flows from the derivative treated as a cash flow hedge is classified in the Company’s consolidated statements of cash flows in the same category as the item being hedged. For the three and six months ended June 30, 2023, the Company included an immaterial gain on the hedged instrument (variable-rate borrowings) in the same line item (interest expense, net) as the offsetting gain on the related interest rate swap in the unaudited consolidated statements of operations and comprehensive loss. The following table summarizes the location of the interest rate swap in the unaudited consolidated balance sheets: Consolidated balance sheets location June 30, 2023 December 31, 2022 Interest rate swap Other noncurrent assets $ 5,611 $ 4,426 The amount of estimated cash flow hedge unrealized gains and losses that are expected to be reclassified to earnings in the next twelve months is not material. Fair Value Measured on a Recurring Basis The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2023 December 31, 2022 Assets Measured at Fair Value Money market funds $ 57,021 $ — Level 1 $ 57,021 $ — Interest rate swap asset $ 5,611 $ 4,426 Level 2 $ 5,611 $ 4,426 Total assets measured at fair value $ 62,632 $ 4,426 Liabilities Measured at Fair Value Contingent consideration liability: Beginning balance $ 17,824 $ 17,430 Additions related to acquisitions 1,985 11,221 Payments of contingent consideration ( 5,201 ) ( 12,515 ) (Gain) loss on remeasurement ( 2,576 ) 1,688 Ending balance 12,032 17,824 Level 3 $ 12,032 $ 17,824 Total liabilities measured at fair value $ 12,032 $ 17,824

Long - Term Debt

Long - Term Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Long-term Debt	NOTE 9 LONG-TERM DEBT On May 4, 2022, the Company entered into a credit agreement (the “2022 Credit Agreement”) among LifeStance Health Holdings, Inc., Lynnwood Intermediate Holdings, Inc., Capital One, National Association, and each lender party thereto. The 2022 Credit Agreement established commitments in respect of a term loan facility of $ 200,000 , a revolving loan facility of up to $ 50,000 and a delayed draw term loan facility of up to $ 100,000 . The commitments under the term loan facility and the revolving facility were available to be drawn on May 16, 2022. The Company borrowed $ 200,000 in term loans on that date, with a maturity date of May 16, 2028 . The remaining commitments under the delayed draw term loan facility are scheduled to terminate on the second anniversary of May 16, 2022 . Once drawn upon, the delayed draw term loan facility has a maturity date of May 16, 2028. The loans under the term loan facility and the delayed draw term loan facility bear interest at a rate per annum equal to (x) adjusted term SOFR (which adjusted term SOFR is subject to a minimum of 0.75 %) plus an applicable margin of 4.50 % or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.50 % above the federal funds effective rate and (iii) one-month adjusted term SOFR (which adjusted term SOFR is subject to a minimum of 0.75 %) plus 1.00 %) plus an applicable margin of 3.50 %. The term loans are collateralized by substantially all of the assets of the Company. The revolving loan has interest only payments until the maturity date of May 16, 2027 . The 2022 Credit Agreement requires the Company to maintain compliance with certain restrictive financial covenants related to earnings, leverage ratios, and other financial metrics. The Company was in compliance with all debt covenants at June 30, 2023 and December 31, 2022. Long-term debt consists of the following: June 30, 2023 December 31, 2022 Term loans $ 198,500 $ 199,500 Delayed Draw loans 59,291 34,464 Total long-term debt 257,791 233,964 Less: Current portion of long-term debt ( 2,595 ) ( 2,345 ) Less: Unamortized discount and debt issue costs (1) ( 6,478 ) ( 6,540 ) Total Long-Term Debt, Net of Current Portion $ 248,718 $ 225,079 (1) The unamortized debt issue costs related to long-term debt are presented as a reduction of the carrying amount of the corresponding liabilities on the unaudited consolidated balance sheets. Unamortized debt issue costs related to delayed draw term loan commitments and revolving loans are presented within other noncurrent assets on the unaudited consolidated balance sheets. The current portion of long-term debt is included within other current liabilities on the unaudited consolidated balance sheets. Interest expense, net consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Interest expense, net $ 5,119 $ 7,133 $ 10,211 $ 10,574 Future principal payments on long-term debt as of June 30, 2023 are as follows: Year Ended December 31, Amount Remainder of 2023 $ 1,298 2024 2,595 2025 2,595 2026 2,595 2027 2,595 Thereafter 246,113 Total $ 257,791 The fair value of long-term debt is based on the present value of future payments discounted by the market interest rates or the fixed rates based on current rates offered to the Company for debt with similar terms and maturities, which is a Level 2 fair value measurement. Long-term debt is presented at carrying value on the unaudited consolidated balance sheets. The fair value of long-term debt at June 30, 2023 and December 31, 2022 was $ 262,681 and $ 235,049 , respectively. Revolving Loan Under the 2022 Credit Agreement, the Company has a revolving loan commitment from Capital One in the amount of $ 50,000 . Any borrowing on the revolving loan under the 2022 Credit Agreement is due in full on May 16, 2027 . The revolving loan bears interest at a rate per annum equal to (x) adjusted term SOFR plus an applicable margin of 3.25 % or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.50 % above the federal funds effective rate and (iii) one-month adjusted term SOFR plus 1.00 %) plus an applicable margin of 2.25 %. The unused revolving loan incurs a commitment fee of 0.50 % per annum. In April 2023, the Company drew $ 25,000 from the aforementioned revolving loan and converted the outstanding balance on the revolving loan to a delayed draw term loan in May 2023. There are no amounts outstanding on the revolving loan as of June 30, 2023 and December 31, 2022 .

Stock - Based Compensation

Stock - Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation	NOTE 10 STOCK-BASED COMPENSATION 2021 Equity Incentive Plan Effective June 9, 2021, the Company’s Board of Directors (the "Board") and its stockholders as of that date adopted and approved the LifeStance Health Group, Inc. 2021 Equity Incentive Plan (the “2021 Equity Incentive Plan”). The 2021 Equity Incentive Plan permits the grant of awards or restricted or unrestricted common stock, stock options, stock appreciation rights, restricted stock units, performance awards, and other stock-based awards to employees and directors of, and consultants and advisors to, the Company and its affiliates. On January 1, 2023, the number of shares of common stock reserved and available for issuance under the 2021 Equity Incentive Plan increased by 18,798 shares. Restricted Stock Awards ("RSA") The following is a summary of RSA transactions as of and for the six months ended June 30, 2023: Unvested Shares Weighted-Average Unvested, December 31, 2022 16,796 $ 11.98 Vested ( 9,095 ) 11.98 Forfeited ( 1,965 ) 11.98 Unvested, June 30, 2023 5,736 $ 11.98 Restricted Stock Units ("RSU") The following is a summary of RSU transactions as of and for the six months ended June 30, 2023: Unvested Shares Weighted-Average Outstanding, December 31, 2022 14,203 $ 10.61 Granted 17,755 6.08 Vested ( 4,006 ) 12.86 Canceled and forfeited ( 2,143 ) 9.39 Outstanding, June 30, 2023 25,809 $ 7.25 Stock Options The following is a summary of stock option activity as of and for the six months ended June 30, 2023: Number of Options Weighted-Average Weighted-Average Aggregate Intrinsic Value Outstanding, December 31, 2022 13,476 $ 7.42 9.70 $ — Granted — — Exercised — — — Canceled and forfeited — — Outstanding, June 30, 2023 13,476 $ 7.42 9.21 $ 23,083 Vested or expected to vest at June 30, 2023 13,476 $ 7.42 9.21 $ 23,083 Stock-Based Compensation Expense The Company recognized stock-based compensation expense related to RSAs, RSUs, and stock options within general and administrative expenses in the unaudited consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock-based compensation expense $ 33,078 $ 57,510 $ 56,944 $ 117,365 As of June 30, 2023, the Company had $ 199,683 in unrecognized compensation expense related to all non-vested awards (RSAs, RSUs and stock options) that will be recognized over the weighted-average remaining service period of 2.4 years. 2021 Employee Stock Purchase Plan Effective June 9, 2021, the Board and its stockholders as of that date adopted and approved the LifeStance Health Group, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP is more fully described in Note 14 in the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. As of June 30, 2023 , no shares of common stock have been purchased under the Company’s ESPP.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 INCOME TAXES The (benefit) provision for income taxes is as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 (Benefit) provision for income taxes $ ( 6,542 ) $ 923 $ ( 10,579 ) $ ( 5,753 ) The effective tax rates are as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Effective tax rate 12.6 % ( 1.4 )% 11.7 % 4.2 % The difference between the Company’s effective tax rate and the U.S. statutory tax rate of 21 % was prima rily the result of non-deductible equity awards. The Company regularly evaluates the realizability of its deferred tax assets and establishes a valuation allowance if it is more likely than not that some or all the deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 12 COMMITMENTS AND CONTINGENCIES Professional Liability Insurance The medical malpractice insurance coverage is subject to a $ 3,000 per claim limit and an annual aggregate shared limit of $ 8,000 . Should the claims-made policy not be renewed or replaced with equivalent insurance, claims based on occurrences during its term, but reported subsequently, would be uninsured. The Company is not aware of any unasserted claims, unreported incidents, or claims outstanding that are expected to exceed malpractice insurance coverage limits as of June 30, 2023 and December 31, 2022. Health Care Industry The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, and government health care program participation requirements, reimbursement for patient services, and Medicare fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by health care providers. Violation of these laws and regulations could result in expulsion from government health care programs together with imposition of significant fines and penalties, as well as significant repayments for patient services billed. Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care companies have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in companies entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Management believes that the Company is in substantial compliance with fraud and abuse as well as other applicable government laws and regulations. While no regulatory inquiries have been made, compliance with such laws and regulations is subject to government review and interpretation, as well as regulatory actions unknown or unasserted at this time. General Contingencies The Company is exposed to various risks of loss related to torts; theft of, damage to and destruction of assets; errors and omissions, injuries to employees, and natural disasters. These risks are covered by commercial insurance purchased from independent third parties. There has been no significant reduction in insurance coverage from the previous year in any of the Company’s policies. Litigation The Company may be involved from time-to-time in legal actions relating to the ownership and operations of its business. Liabilities related to loss contingencies are recognized when the Company believes it is probable a liability has occurred and the amount can be reasonably estimated by management. The Company will establish an accrual for those legal proceedings and regulatory matters for which a loss is both probable and the amount can be reasonably estimated. On August 10, 2022, a shareholder class action lawsuit captioned Nayani v. LifeStance Health Group, Inc., et al. was filed in the United States District Court for the Southern District of New York (the “Court”) against the Company and certain executives and board members (the “LifeStance Defendants”), as well as the underwriters of the Company’s initial public offering (the “IPO”) (collectively, “Defendants”). The lawsuit alleges, in part, that the Defendants violated Section 11 of the Securities Act of 1933 (the “Securities Act”) because the IPO registration statement purportedly contained inaccurate and misleading statements and/or failed to disclose certain facts concerning patient visits and clinician retention. The lawsuit also asserts that the LifeStance Defendants violated Section 15 of the Securities Act because they are control persons of the Company. The lawsuit seeks unspecified monetary damages and purports to represent all shareholders who purchased the Company’s common stock pursuant to the IPO registration statement. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted. The Company has not recorded any material accruals for loss contingencies and in management's opinion no material range of loss is estimable for this matter as of June 30, 2023 .

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	NOTE 13 NET LOSS PER SHARE The following table presents the calculation of basic and diluted net loss per share (“EPS”) for the Company’s common shares: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Net loss available to common stockholders' $ ( 45,478 ) $ ( 68,727 ) $ ( 79,720 ) $ ( 131,055 ) Weighted-average shares used to compute basic and 363,161 353,729 362,039 352,297 Net loss per share, basic and diluted $ ( 0.13 ) $ ( 0.19 ) $ ( 0.22 ) $ ( 0.37 ) The Company has issued potentially dilutive instruments in the form of RSAs, RSUs and stock options. The Company did not include any of these instruments in its calculation of diluted loss per share for the three and six months ended June 30, 2023 and 2022 because to include them would be anti-dilutive due to the Company’s net loss during the period. See Note 10 for the issued, vested and unvested RSAs, RSUs and stock options. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share: As of June 30, 2023 2022 RSAs 5,736 19,081 RSUs 25,809 14,994 Stock options 13,476 — 45,021 34,075

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Company has prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the SEC regarding interim financial reporting, which include the accounts of LifeStance, its wholly-owned subsidiaries and variable interest entities ("VIEs") in which LifeStance has an interest and is the primary beneficiary. Pursuant to these rules and regulations, the Company has omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its consolidated financial condition, results of operations and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s audited financial statements for the year ended December 31, 2022 in the Company's Annual Report on Form 10-K.
Use of Accounting Estimates	Use of Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a VIE. These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available information. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. The Company performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. The Company acquires and operates certain care centers which are deemed to be Friendly-Physician Entities (“FPEs”). As part of an FPE acquisition, the Company acquires 100 % of the non-medical assets, however due to legal requirements the physician-owners must retain 100% of the equity interest. The Company’s agreements with FPEs generally consist of both a Management Service Agreement, which provides for various administrative and management services to be provided by the Company to the FPE, and Stock Transfer Restriction (“STR”) agreements with the physician-owners of the FPEs, which provide for the transition of ownership interests of the FPEs under certain conditions. The outstanding voting equity instruments of the FPEs are owned by the nominee shareholders appointed by the Company under the terms of the STR agreements. The Company has the right to receive income as an ongoing management fee, which effectively absorbs all of the residual interests and has also provided financial support through loans to the FPEs. The Company has exclusive responsibility for the provision of all nonmedical services including facilities, technology and intellectual property required for the day-to-day operation and management of each of the FPEs, and makes recommendations to the FPEs in establishing the guidelines for the employment and compensation of the physicians and other employees of the FPEs. In addition, the STR agreements provide that the Company has the right to designate an appropriately licensed person(s) to purchase the equity interest of the FPE for a nominal amount in the event of a succession event at the Company’s discretion. Based on the provisions of these agreements, the Company determined that the FPEs are VIEs due to the equity holder having insufficient capital at risk, and the Company has a variable interest in the FPEs. The contractual arrangements described above allow the Company to direct the activities that most significantly affect the economic performance of the FPEs. Accordingly, the Company is the primary beneficiary of the FPEs and consolidates the FPEs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support the Company provides to the FPEs (e.g., loans) and the provisions of the contractual arrangements and nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the FPEs. Therefore, all income and expenses recognized by the FPEs are allocated to the Company. The Company does not hold interests in any VIEs for which the Company is not deemed to be the primary beneficiary. As noted previously, the Company acquires 100% of the non-medical assets of the VIEs. The aggregate carrying values of the VIEs total assets and total liabilities not purchased by the Company but included on the consolidated balance sheets were not material at June 30, 2023 and December 31, 2022 .
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash and highly liquid investments with original maturities of three months or less at the time of purchase. Cash and cash equivalents consist of demand deposits held with financial institutions and investments in money market funds.
Emerging Growth Company Status	Emerging Growth Company Status The Company is currently an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company's unaudited consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. As of June 30, 2023, the market value of the Company's common stock held by non-affiliates exceeded $ 700 million. As a result, the Company will become a large accelerated filer beginning January 1, 2024 for future filings and will no longer be an emerging growth company. As a large accelerated filer, the Company will be subject to certain disclosure and compliance requirements that apply to other public companies but did not previously apply to the Company due to its status as an emerging growth company. These requirements include, but are not limited to: the requirement that the Company's independent registered public accounting firm attest to the effectiveness of the Company's internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002; compliance with any requirements that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditors' report providing additional information about the audit and the financial statements; the requirement that the Company provide more detailed disclosures regarding executive compensation; and, the requirement that the Company hold a non-binding advisory vote on executive compensation and obtain shareholder approval of any golden parachute payments not previously approved.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments (Topic 326)-Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires an entity to utilize a new impairment model known as the current expected credit loss (“CECL”) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The estimate of expected credit losses requires entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the standard on January 1, 2023 using the modified retrospective adoption method and did not have a material impact to the consolidated financial statements. The Company makes estimates of expected credit losses based on a combination of factors, including historical losses adjusted for current market conditions, the Company's customers' financial condition, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Total Revenue (Tables)

Total Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Disaggregation of Revenue [Abstract]
Schedule of revenue from patients and third - party payors	The payor mix of fee-for-service revenue from patients and third-party payors consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Amount % of Total Revenue Amount % of Total Revenue Amount % of Total Revenue Amount % of Total Revenue Commercial $ 235,896 91 % $ 189,061 91 % $ 464,815 91 % $ 372,670 91 % Government 10,999 4 % 9,063 4 % 21,950 4 % 17,896 4 % Self-pay 10,384 4 % 8,723 4 % 20,131 4 % 17,098 4 % Total patient service 257,279 99 % 206,847 99 % 506,896 99 % 407,664 99 % Nonpatient service 2,299 1 % 2,680 1 % 5,271 1 % 4,958 1 % Total $ 259,578 100 % $ 209,527 100 % $ 512,167 100 % $ 412,622 100 %
Schedule of percentage of revenue from insurance companies	Among the commercial payors, the table below represents insurance companies that individually represented 10 % or more of revenue: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Payor A 19 % 19 % 19 % 19 % Payor B 13 % 14 % 13 % 14 %

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following: June 30, 2023 December 31, 2022 Leasehold improvements $ 162,494 $ 148,249 Computers and peripherals 27,701 26,650 Internal-use software 8,352 7,894 Furniture, fixtures and equipment 40,709 36,437 Medical equipment 950 950 Construction in process 11,285 16,892 Total $ 251,491 $ 237,072 Less: Accumulated depreciation ( 58,347 ) ( 42,883 ) Total property and equipment, net $ 193,144 $ 194,189
Schedule of Depreciation Expense	Depreciation expense consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Depreciation expense $ 9,354 $ 6,750 $ 18,250 $ 12,477

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Summary of Components of Lease Expense	The components of lease expense for the Company's operating leases in its unaudited consolidated statements of operations and comprehensive loss were as follows: Three Months Ended Six Months Ended Operating lease costs $ 14,264 $ 28,572 Variable lease costs and short-term lease costs were no t material. The weighted-average remaining lease term and discount rate for operating lease liabilities included in the consolidated balance sheets are as follows: June 30, 2023 December 31, 2022 Weighted-average remaining lease term (in years) 5.0 5.3 Weighted-average discount rate 6.77 % 6.47 %
Summary of Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases was as follows: Six Months Ended Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 30,995 Noncash lease activity Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 14,554
Summary of Future Minimum Lease Payments	The future minimum lease payments under noncancellable operating leases as of June 30, 2023 are as follows: Year Ended December 31, Amount Remainder of 2023 $ 25,987 2024 64,960 2025 61,345 2026 53,713 2027 40,457 Thereafter 49,810 Total lease payments $ 296,272 Less: imputed interest ( 47,240 ) Total lease liabilities $ 249,032
Schedule of Unaudited Consolidated Balance Sheets in Connection with Leases with Related Parties	The Company recognized the following amounts in its unaudited consolidated balance sheets in connection with leases with related parties: June 30, 2023 December 31, 2022 Right-of-use assets $ 2,770 $ 5,058 Operating lease liabilities, current 549 1,324 Operating lease liabilities, noncurrent 2,315 3,902
Schedule of Total Rent Expense	Total rent expense amounted to as follows in the unaudited consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022: Three Months Ended Six Months Ended Related-party rent expense $ 391 $ 778 Third-party rent expense 12,137 23,296 Total lease cost $ 12,528 $ 24,074

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill	The following table summarizes changes in the carrying amount of goodwill: Amount Balance as of December 31, 2022 $ 1,272,939 Business acquisitions (Note 7) 20,733 Measurement period adjustments ( 170 ) Balance as of June 30, 2023 $ 1,293,502
Summary of Intangible Assets	Intangible assets consist of the following: June 30, 2023 Gross Accumulated Net Weighted Regional trade names $ 36,694 $ ( 20,358 ) $ 16,336 5.0 LifeStance trade names 235,500 ( 32,791 ) 202,709 22.5 Non-competition agreements 94,535 ( 69,792 ) 24,743 4.2 Total intangible assets $ 366,729 $ ( 122,941 ) $ 243,788 December 31, 2022 Gross Accumulated Net Weighted Regional trade names $ 36,259 $ ( 16,688 ) $ 19,571 5.0 LifeStance trade names 235,500 ( 27,557 ) 207,943 22.5 Non-competition agreements 94,127 ( 58,347 ) 35,780 4.2 Total intangible assets $ 365,886 $ ( 102,592 ) $ 263,294
Summary of Intangible Assets Amortization Expense	Gross carrying amount is based on the fair value of the intangible assets determined at the acquisition date. Total intangible asset amortization expense consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Amortization expense $ 10,176 $ 9,993 $ 20,349 $ 19,950

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2023
Business Combinations [Abstract]
Summary Of Consideration Transferred	Total consideration transferred for these acquisitions consisted of the following: Three Months Ended Six Months Ended June 30, June 30, 2022 2023 2022 Cash consideration $ 12,600 $ 20,000 $ 35,925 Contingent consideration, at initial fair value 3,213 1,985 5,683 Total consideration transferred $ 15,813 $ 21,985 $ 41,608
Schedule of Recognized Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary fair values of assets acquired and liabilities assumed as of the dates of acquisition: Three Months Ended Six Months Ended June 30, Allocation of Purchase Price June 30, 2022 2023 2022 Cash $ 430 $ 181 $ 851 Patient accounts receivable 707 372 1,193 Prepaid expenses and other current assets 166 138 230 Property and equipment 19 221 53 Right-of-use assets — 368 — Other noncurrent assets 53 22 56 Intangible assets 901 843 1,683 Goodwill 14,526 20,733 39,227 Total assets acquired 16,802 22,878 43,293 Total liabilities assumed 989 893 1,685 Fair value of net assets $ 15,813 $ 21,985 $ 41,608 The majority of the tangible assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. The Company developed estimates for the expected future cash flows and discount rates used in the present value calculations.
Schedule of Fair Values of Acquired Intangible Assets	The following table summarizes the fair values of acquired intangible assets as of the dates of acquisition: Three Months Ended Six Months Ended June 30, June 30, 2022 2023 2022 Regional trade names (1) $ 555 $ 435 $ 897 Non-competition agreements (2) 346 408 786 Total $ 901 $ 843 $ 1,683 (1) Useful lives for regional trade names are 5 years . (2) Useful lives for non-competition agreements are 5 years .
Schedule of Maximum Contingent Consideration Based on the Acquisition Agreements	The following table summarizes the maximum contingent consideration based on the acquisition agreements: Three Months Ended Six Months Ended June 30, Contingent consideration June 30, 2022 2023 2022 Maximum contingent consideration based on acquisition $ 4,200 $ 2,650 $ 7,200

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of the Significant Assumptions Used for the Fair Value Measurement of the Contingent Consideration Liability	The following is the summary of the significant assumptions used for the fair value measurement of the contingent consideration liability as of June 30, 2023 and December 31, 2022. Valuation Technique Range of Significant Assumptions June 30, 2023 December 31, 2022 Probability-weighted analysis Probability 50 % - 100 % 50 % - 100 % based earn-outs Discount rate 9.0 % 8.0 %
Schedule of Location of the Interest Rate Swap	The following table summarizes the location of the interest rate swap in the unaudited consolidated balance sheets: Consolidated balance sheets location June 30, 2023 December 31, 2022 Interest rate swap Other noncurrent assets $ 5,611 $ 4,426
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: June 30, 2023 December 31, 2022 Assets Measured at Fair Value Money market funds $ 57,021 $ — Level 1 $ 57,021 $ — Interest rate swap asset $ 5,611 $ 4,426 Level 2 $ 5,611 $ 4,426 Total assets measured at fair value $ 62,632 $ 4,426 Liabilities Measured at Fair Value Contingent consideration liability: Beginning balance $ 17,824 $ 17,430 Additions related to acquisitions 1,985 11,221 Payments of contingent consideration ( 5,201 ) ( 12,515 ) (Gain) loss on remeasurement ( 2,576 ) 1,688 Ending balance 12,032 17,824 Level 3 $ 12,032 $ 17,824 Total liabilities measured at fair value $ 12,032 $ 17,824

Long - Term Debt (Tables)

Long - Term Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Summary of Long-term Debt Instruments	Long-term debt consists of the following: June 30, 2023 December 31, 2022 Term loans $ 198,500 $ 199,500 Delayed Draw loans 59,291 34,464 Total long-term debt 257,791 233,964 Less: Current portion of long-term debt ( 2,595 ) ( 2,345 ) Less: Unamortized discount and debt issue costs (1) ( 6,478 ) ( 6,540 ) Total Long-Term Debt, Net of Current Portion $ 248,718 $ 225,079 (1) The unamortized debt issue costs related to long-term debt are presented as a reduction of the carrying amount of the corresponding liabilities on the unaudited consolidated balance sheets. Unamortized debt issue costs related to delayed draw term loan commitments and revolving loans are presented within other noncurrent assets on the unaudited consolidated balance sheets.
Summary of Interest Expense	Interest expense, net consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Interest expense, net $ 5,119 $ 7,133 $ 10,211 $ 10,574
Summary of Maturities of Long-term Debt	Future principal payments on long-term debt as of June 30, 2023 are as follows: Year Ended December 31, Amount Remainder of 2023 $ 1,298 2024 2,595 2025 2,595 2026 2,595 2027 2,595 Thereafter 246,113 Total $ 257,791

Stock- Based Compensation (Tabl

Stock- Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Restricted Stock Awards (RSA) Activity	The following is a summary of RSA transactions as of and for the six months ended June 30, 2023: Unvested Shares Weighted-Average Unvested, December 31, 2022 16,796 $ 11.98 Vested ( 9,095 ) 11.98 Forfeited ( 1,965 ) 11.98 Unvested, June 30, 2023 5,736 $ 11.98
Summary of Restricted Stock Unit (RSU) Activity	The following is a summary of RSU transactions as of and for the six months ended June 30, 2023: Unvested Shares Weighted-Average Outstanding, December 31, 2022 14,203 $ 10.61 Granted 17,755 6.08 Vested ( 4,006 ) 12.86 Canceled and forfeited ( 2,143 ) 9.39 Outstanding, June 30, 2023 25,809 $ 7.25
Summary of Stock Option Activity	The following is a summary of stock option activity as of and for the six months ended June 30, 2023: Number of Options Weighted-Average Weighted-Average Aggregate Intrinsic Value Outstanding, December 31, 2022 13,476 $ 7.42 9.70 $ — Granted — — Exercised — — — Canceled and forfeited — — Outstanding, June 30, 2023 13,476 $ 7.42 9.21 $ 23,083 Vested or expected to vest at June 30, 2023 13,476 $ 7.42 9.21 $ 23,083
Summary of Stock Based Compensation Expense	The Company recognized stock-based compensation expense related to RSAs, RSUs, and stock options within general and administrative expenses in the unaudited consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock-based compensation expense $ 33,078 $ 57,510 $ 56,944 $ 117,365

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Tax Expense (Benefit)	The (benefit) provision for income taxes is as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 (Benefit) provision for income taxes $ ( 6,542 ) $ 923 $ ( 10,579 ) $ ( 5,753 )
Schedule of Effective Tax Rates	The effective tax rates are as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Effective tax rate 12.6 % ( 1.4 )% 11.7 % 4.2 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table presents the calculation of basic and diluted net loss per share (“EPS”) for the Company’s common shares: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Net loss available to common stockholders' $ ( 45,478 ) $ ( 68,727 ) $ ( 79,720 ) $ ( 131,055 ) Weighted-average shares used to compute basic and 363,161 353,729 362,039 352,297 Net loss per share, basic and diluted $ ( 0.13 ) $ ( 0.19 ) $ ( 0.22 ) $ ( 0.37 )
Computation of Diluted Net Loss per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share: As of June 30, 2023 2022 RSAs 5,736 19,081 RSUs 25,809 14,994 Stock options 13,476 — 45,021 34,075

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Business Acquisition, Contingent Consideration [Line Items]
Schedule of Maximum Contingent Consideration Based on the Acquisition Agreements	The following table summarizes the maximum contingent consideration based on the acquisition agreements: Three Months Ended Six Months Ended June 30, Contingent consideration June 30, 2022 2023 2022 Maximum contingent consideration based on acquisition $ 4,200 $ 2,650 $ 7,200
Schedule Of Related-party Rent Expense	Total rent expense amounted to as follows in the unaudited consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022: Three Months Ended Six Months Ended Related-party rent expense $ 391 $ 778 Third-party rent expense 12,137 23,296 Total lease cost $ 12,528 $ 24,074
Summary of Future Minimum Lease Payments	The future minimum lease payments under noncancellable operating leases as of June 30, 2023 are as follows: Year Ended December 31, Amount Remainder of 2023 $ 25,987 2024 64,960 2025 61,345 2026 53,713 2027 40,457 Thereafter 49,810 Total lease payments $ 296,272 Less: imputed interest ( 47,240 ) Total lease liabilities $ 249,032

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Schedule Of Related-party Rent Expense	Total rent expense amounted to as follows in the unaudited consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022: Three Months Ended Six Months Ended Related-party rent expense $ 391 $ 778 Third-party rent expense 12,137 23,296 Total lease cost $ 12,528 $ 24,074

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ in Millions	Jun. 30, 2023 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Acquisition of Non Medical Assets	100%
Common stock held by non affiliates	$ 700

Total Revenue - Additional Info

Total Revenue - Additional Information (Details)	Mar. 31, 2023
Minimum [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
% of Total Revenue	10%

Total Revenue - Schedule of Rev

Total Revenue - Schedule of Revenue From Patients And Third - Party Payors (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Amount	$ 259,578	$ 209,527	$ 512,167	$ 412,622
% of Total Revenue	100%	100%	100%	100%
Commercial
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Amount	$ 235,896	$ 189,061	$ 464,815	$ 372,670
% of Total Revenue	91%	91%	91%	91%
Government
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Amount	$ 10,999	$ 9,063	$ 21,950	$ 17,896
% of Total Revenue	4%	4%	4%	4%
Self-pay
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Amount	$ 10,384	$ 8,723	$ 20,131	$ 17,098
% of Total Revenue	4%	4%	4%	4%
Total patient service revenue
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Amount	$ 257,279	$ 206,847	$ 506,896	$ 407,664
% of Total Revenue	99%	99%	99%	99%
Nonpatient service revenue
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Amount	$ 2,299	$ 2,680	$ 5,271	$ 4,958
% of Total Revenue	1%	1%	1%	1%

Total Revenue - Schedule of Per

Total Revenue - Schedule of Percentage Of Revenue From Insurance Companies (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Health Care Organization Receivable And Revenue Disclosures [Line Items]
% of Total Revenue	100%	100%	100%	100%
Payor A
Health Care Organization Receivable And Revenue Disclosures [Line Items]
% of Total Revenue	19%	19%	19%	19%
Payor B
Health Care Organization Receivable And Revenue Disclosures [Line Items]
% of Total Revenue	13%	14%	13%	14%

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Total	$ 251,491	$ 237,072
Less: Accumulated depreciation	(58,347)	(42,883)
Total property and equipment, net	193,144	194,189
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Total	162,494	148,249
Computers and Peripherals [Member]
Property Plant And Equipment [Line Items]
Total	27,701	26,650
Internal-use software [Member]
Property Plant And Equipment [Line Items]
Total	8,352	7,894
Furniture, Fixtures and Equipment [Member]
Property Plant And Equipment [Line Items]
Total	40,709	36,437
Medical Equipment [Member]
Property Plant And Equipment [Line Items]
Total	950	950
Construction in Process [Member]
Property Plant And Equipment [Line Items]
Total	$ 11,285	$ 16,892

Property and Equipment, Net -_2

Property and Equipment, Net - Schedule of Depreciation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 9,354	$ 6,750	$ 18,250	$ 12,477

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Operating Cost and Expense, Related and Nonrelated Party Status [Extensible Enumeration]	Related party	Related party
Operating lease costs	$ 14,264	$ 28,572
Variable lease costs		0
Short-term lease costs		0
Related party
Lessee, Lease, Description [Line Items]
Related party lease expenses	$ 205	$ 417
Maximum
Lessee, Lease, Description [Line Items]
Operating leases renewal term	7 years	7 years
Minimum
Lessee, Lease, Description [Line Items]
Operating leases renewal term	1 year	1 year

Leases - Summary of Components

Leases - Summary of Components of Lease Expense for the Company's Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Leases [Abstract]
Operating lease costs	$ 14,264	$ 28,572

Leases - Summary of Weighted Av

Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Weighted-average remaining lease term (in years)	5 years	5 years 3 months 18 days
Weighted-average discount rate	6.77%	6.47%

Leases - Summary of Supplementa

Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$ 30,995
Non Cash Leases Activity Abstract
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$ 14,554

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Leases [Abstract]
Remainder of 2023	$ 25,987
2024	64,960
2025	61,345
2026	53,713
2027	40,457
Thereafter	49,810
Total lease payments	296,272
Less: imputed interest	(47,240)
Total lease liabilities	$ 249,032

Leases - Schedule of Unaudited

Leases - Schedule of Unaudited Consolidated Balance Sheets in Connection with Leases with Related Parties (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Right-of-use assets	$ 191,381	$ 199,431
Operating lease liabilities, current	43,446	38,824
Operating lease liabilities, noncurrent	205,586	212,586
Related party
Right-of-use assets	2,770	5,058
Operating lease liabilities, current	549	1,324
Operating lease liabilities, noncurrent	$ 2,315	$ 3,902

Leases - Schedule Of Total Rent

Leases - Schedule Of Total Rent Expense (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Operating Leased Assets [Line Items]
Total lease cost	$ 12,528	$ 24,074
Third Party
Operating Leased Assets [Line Items]
Total lease cost	12,137	23,296
Related party
Operating Leased Assets [Line Items]
Total lease cost	$ 391	$ 778

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Summary of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Line Items]
Beginning balance	$ 1,272,939
Business acquisitions	20,733
Measurement period adjustment	(170)
Ending balance	$ 1,293,502

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 366,729	$ 365,886
Accumulated Amortization	(122,941)	(102,592)
Net Carrying Amount	243,788	263,294
Regional Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	36,694	36,259
Accumulated Amortization	(20,358)	(16,688)
Net Carrying Amount	$ 16,336	$ 19,571
Weighted Average Useful Life (Years)	5 years	5 years
Life Stance Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 235,500	$ 235,500
Accumulated Amortization	(32,791)	(27,557)
Net Carrying Amount	$ 202,709	$ 207,943
Weighted Average Useful Life (Years)	22 years 6 months	22 years 6 months
Non-Competition Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 94,535	$ 94,127
Accumulated Amortization	(69,792)	(58,347)
Net Carrying Amount	$ 24,743	$ 35,780
Weighted Average Useful Life (Years)	4 years 2 months 12 days	4 years 2 months 12 days

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Summary of Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 10,176	$ 9,993	$ 20,349	$ 19,950

Business Combinations - Additio

Business Combinations - Additional Information (Details) - Facility	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Combinations [Abstract]
Acquisitions of outpatient mental health practices	0	4	3	6

Business Combinations - Summary

Business Combinations - Summary of Consideration Transferred (Details) - Outpatient Mental Health Practices - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Acquisition [Line Items]
Cash consideration	$ 12,600	$ 20,000	$ 35,925
Total consideration transferred	15,813	21,985	41,608
Class A-2 Common Units [Member]
Business Acquisition [Line Items]
Contingent consideration, at initial fair value	$ 3,213	$ 1,985	$ 5,683

Business Combinations - Schedul

Business Combinations - Schedule of Fair Value Assets Acquired And Liabilities Assumed (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Combinations [Abstract]
Cash	$ 430	$ 181	$ 851
Patient accounts receivable	707	372	1,193
Prepaid expenses and other current assets	166	138	230
Property and equipment	19	221	53
Right-of-use assets	0	368	0
Other noncurrent assets	53	22	56
Intangible assets	901	843	1,683
Goodwill	14,526	20,733	39,227
Total assets acquired	16,802	22,878	43,293
Total liabilities assumed	989	893	1,685
Fair value of net assets	$ 15,813	$ 21,985	$ 41,608

Business Combinations - Sched_2

Business Combinations - Schedule of Fair Values of Acquired Intangible Assets (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
		Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Business Acquisition [Line Items]
Acquired intangible assets, Fair value		$ 901	$ 843	$ 1,683
Regional Trade Names [Member]
Business Acquisition [Line Items]
Acquired intangible assets, Fair value	[1]	555	435	897
Non-Competition Agreements [Member]
Business Acquisition [Line Items]
Acquired intangible assets, Fair value	[2]	$ 346	$ 408	$ 786
[1] Useful lives for regional trade names are 5 years . Useful lives for non-competition agreements are 5 years .

Business Combinations - Sched_3

Business Combinations - Schedule of Fair Values of Acquired Intangible Assets (Parenthetical) (Details)	Jun. 30, 2023
Regional Trade Names [Member]
Business Acquisition [Line Items]
Useful lives for acquired intangible assets	5 years
Non-Competition Agreements [Member]
Business Acquisition [Line Items]
Useful lives for acquired intangible assets	5 years

Business Combinations - Sched_4

Business Combinations - Schedule of Maximum Contingent Consideration Based on the Acquisition Agreements (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Contingent Consideration [Member]
Business Acquisition [Line Items]
Maximum contingent consideration based on acquisition agreements	$ 4,200	$ 2,650	$ 7,200

Fair Value Measurements - Summa

Fair Value Measurements - Summary of the Significant Assumptions Used for the Fair Value Measurement of the Contingent Consideration Liability (Details)	Jun. 30, 2023	Dec. 31, 2022
Minimum | Probability Weighted Analysis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.50	0.50
Minimum | F T E Based Earn Outs
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.09	0.08
Maximum | Probability Weighted Analysis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	1	1

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of location of the interest rate swap (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset	$ 62,632	$ 4,426
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other noncurrent assets
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset	$ 5,611	$ 4,426

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Asset	$ 62,632	$ 4,426
Beginning balance	17,824	17,430
Additions related to acquisitions	1,985	11,221
Payments of contingent consideration	(5,201)	(12,515)
(Gain) loss on remeasurement	(2,576)	1,688
Ending balance	12,032	17,824
Derivative Liability	12,032	17,824
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Asset	57,021	0
Interest Rate Swap
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Asset	5,611	4,426
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Asset	57,021	0
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Asset	5,611	4,426
Fair Value, Inputs, Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liability	$ 12,032	$ 17,824

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - Interest Rate Swap - USD ($)	Jun. 30, 2023	Aug. 31, 2022
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Percent of Debt Exposed		94.50%
Cash Flow Hedging
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative, Fixed Interest Rate		3.24%
Derivative, Notional Amount	$ 187,583	$ 189,000

Long - Term Debt - Summary of L

Long - Term Debt - Summary of Long-term Debt Instruments (Detail) - USD ($)		Jun. 30, 2023	Dec. 31, 2022	May 04, 2022
Debt Instrument [Line Items]
Term loans		$ 248,718,000	$ 225,079,000
Less: Current portion of long-term debt		(2,595,000)	(2,345,000)
Less: Unamortized discount and debt issue costs	[1]	(6,478,000)	(6,540,000)
Total		257,791,000	233,964,000
Term Loans
Debt Instrument [Line Items]
Total		198,500,000	199,500,000	$ 200,000
Delayed Drawn Loans
Debt Instrument [Line Items]
Total		$ 59,291,000	$ 34,464,000
[1] The unamortized debt issue costs related to long-term debt are presented as a reduction of the carrying amount of the corresponding liabilities on the unaudited consolidated balance sheets. Unamortized debt issue costs related to delayed draw term loan commitments and revolving loans are presented within other noncurrent assets on the unaudited consolidated balance sheets.

Long - Term Debt - Additional I

Long - Term Debt - Additional Information (Detail) - USD ($)		6 Months Ended
	May 04, 2022	Jun. 30, 2023	Apr. 01, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Long-term Debt, Fair Value		$ 262,681,000		$ 235,049
Long term debt fair value		257,791,000		233,964,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Loan withdrawal amount			$ 25,000,000
Revolving loan outstanding amount			$ 25,000,000
2022 Credit Agreement [Member]
Debt Instrument [Line Items]
Term loan facility	$ 200,000
Debt instrument, basis spread on variable rate	1%
2022 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Loan withdrawal amount		0		0
Maximum borrowing capacity		$ 50,000
Unused revolving loan commitment fee percentage		0.005
Revolving loan outstanding amount		$ 0		0
Revolving loan,expiration date		May 16, 2027
Term Loans
Debt Instrument [Line Items]
Long-term Debt, Maturities, Repayment Terms	May 16, 2028
Long term debt fair value	$ 200,000	$ 198,500,000		199,500,000
Delayed Drawn Loans
Debt Instrument [Line Items]
Long term debt fair value		$ 59,291,000		$ 34,464,000
Maximum | 2022 Credit Agreement [Member]
Debt Instrument [Line Items]
Loan withdrawal amount	50,000
Revolving loan outstanding amount	50,000
Maximum | Delayed Drawn Loans | 2022 Credit Agreement [Member]
Debt Instrument [Line Items]
Aggregate loan commitment amount	$ 100,000
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | 2022 Credit Agreement [Member]
Debt Instrument [Line Items]
Long-term Debt, Maturities, Repayment Terms	May 16, 2027
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum | 2022 Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.75%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum | 2022 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum | 2022 Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	4.50%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum | 2022 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		3.25%
Federal Funds Rate | 2022 Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Federal Funds Rate | 2022 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.50%
Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	3.50%
Base Rate | 2022 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		2.25%

Long - Term Debt - Summary of I

Long - Term Debt - Summary of Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Interest expense, net	$ 5,119	$ 7,133	$ 10,211	$ 10,574

Long - Term Debt - Future Princ

Long - Term Debt - Future Principal Payments on Long Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Remainder of 2023	$ 1,298
2024	2,595
2025	2,595
2026	2,595
2027	2,595
Thereafter	246,113
Total	$ 257,791	$ 233,964

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
(Benefit) provision for income taxes	$ (6,542)	$ 923	$ (10,579)	$ (5,753)

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Tax Rates (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Effective tax rate	12.60%	(1.40%)	11.70%	4.20%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Statutory tax rate	21%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Medical malpractice insurance, coverage per claim limit	$ 3,000
Medical malpractice insurance, annual coverage per clinician	$ 8,000

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss available to common stockholders'	$ (45,478)	$ (68,727)	$ (79,720)	$ (131,055)
Weighted-average shares used to compute basic and diluted net loss per share	363,161	353,729	362,039	352,297
Net loss per share, basic	$ (0.13)	$ (0.19)	$ (0.22)	$ (0.37)
Net loss per share, diluted	$ (0.13)	$ (0.19)	$ (0.22)	$ (0.37)

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Diluted Net Loss per Share (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted net loss per share	45,021	34,075
Restricted Stock Awards RSA [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted net loss per share	5,736	19,081
Restricted Stock Units RSU [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted net loss per share	25,809	14,994
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted net loss per share	13,476	0

Stock - Based Compensation - Ad

Stock - Based Compensation - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jan. 01, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense	$ 199,683
Unrecognized compensattion expense, weighted-average period	2 years 4 months 24 days
2021 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance		18,798
2021 Employee Stock Purchase Plan [Member] | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	0

Stock - Based Compensation - Su

Stock - Based Compensation - Summary of Restricted Stock Awards (RSA) Activity (Details) - Restricted Stock Award	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding | shares	16,796
Vested | shares	(9,095)
Forfeited | shares	(1,965)
Outstanding | shares	5,736
Outstanding | $ / shares	$ 11.98
Vested | $ / shares	11.98
Canceled and forfeited | $ / shares	11.98
Outstanding | $ / shares	$ 11.98

Stock - Based Compensation - _2

Stock - Based Compensation - Summary of Restricted Stock Unit (RSU) Activity (Details) - Restricted Stock Unit	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding | shares	14,203
Granted | shares	17,755
Vested | shares	(4,006)
Canceled and forfeited | shares	(2,143)
Outstanding | shares	25,809
Outstanding | $ / shares	$ 10.61
Granted | $ / shares	6.08
Vested | $ / shares	12.86
Canceled and forfeited | $ / shares	9.39
Outstanding | $ / shares	$ 7.25

Stock - Based Compensation - _3

Stock - Based Compensation - Summary of Stock Option Activity (Details) - Employee Stock Option $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares options outstanding, Beginning Balance | shares	13,476
Number of options, granted | shares	0
Number of options, exercised | shares	0
Number of options, forfeited | shares	0
Number of shares options outstanding, Ending Balance | shares	13,476
Number of shares options, vested or expected to vest | shares	13,476
Weighted average exercise price outstanding, Beginning Balance | $ / shares	$ 7.42
Weighted average exercise price, granted | $ / shares	0
Weighted average exercise price, exercised | $ / shares	0
Weighted average exercise price, forfeited | $ / shares	0
Weighted average exercise price outstanding, Ending Balance | $ / shares	7.42
Weighted average exercise price, vested or expected to vest | $ / shares	$ 7.42
Weighted average remaining term in years, Outstanding, Beginning	9 years 8 months 12 days
Weighted average remaining term in years, Outstanding, Ending	9 years 2 months 15 days
Weighted average remaining contractual life, vested or expected to vest	9 years 2 months 15 days
Aggregate intrinsic value outstanding, Beginning Balance | $	$ 0
Aggregate intrinsic value, exercised | $	0
Aggregate intrinsic value outstanding, Ending Balance | $	23,083
Aggregate intrinsic value, vested or expected | $	$ 23,083

Stock - Based Compensation - _4

Stock - Based Compensation - Summary of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and unit-based compensation expense	$ 33,078	$ 57,510	$ 56,944	$ 117,365

Stockholders'_Members' Equity -

Stockholders'/Members' Equity - Additional Information (Detail) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Subsidiary Sale Of Stock [Line Items]
Common Stock, Shares Authorized	800,000,000	800,000,000
Common Stock, par value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	25,000,000	25,000,000
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding	0	0

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Rent Expenses (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Related Party Transactions [Abstract]
Rent expense	$ 12,528	$ 24,074